Adjuvant activity of synthetic 6-O-"mycoloyl"-N-acetylmuramyl-L-alanyl-D-isoglutamine and related compounds.
Adjuvant and antitumor activities of synthetic 6-O-"mycoloyl"-N-acetylmuramyl-L-alanyl-D-isoglutamine were examined. All the synthetic 6-O-corynomycoloyl-, 6-O-mocardomycoloyl-, and 6-O-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine were active as adjuvants for cell-mediated immune responses. However, 6-O-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine was less active as an adjuvant on circulating antibody formation. It was shown that pyrogenic activity of N-acetylmuramyldipeptide was reduced by 6-O-acylation with mycolic acid, but not with nocardomycolic or corynomycolic acid. Tumor-suppression activity was observed by the synthetic 6-O-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine by using transplantable tumor in syngenic mice.
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives; D000276:Adjuvants, Immunologic; D000818:Animals; D000906:Antibodies; D000920:Antibody-Dependent Cell Cytotoxicity; D004136:Dinitrobenzenes / Q000276:immunology; D005260:Female; D006020:Glycopeptides / Q000276:immunology*; D006168:Guinea Pigs; D007111:Immunity, Cellular; D008211:Lymphocyte Cooperation; D008297:Male; D012515:Mast-Cell Sarcoma / Q000628:therapy; D051379:Mice; D008815:Mice, Inbred Strains; D008934:Mitogens; D009171:Mycolic Acids / Q000276:immunology; D012513:Sarcoma, Experimental / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology
D000276:Adjuvants, Immunologic; D000906:Antibodies; D004136:Dinitrobenzenes; D006020:Glycopeptides; D008934:Mitogens; D009171:Mycolic Acids; C017548:mycoloyl-N-acetylmuramyl-alanylisoglutamine; D000119:Acetylmuramyl-Alanyl-Isoglutamine